Clearside Biomedical (BST:CLM) - Aandelenkoers, Nieuws & Analyse

CLM Overzicht aandelen

A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.

Over het bedrijf

CLM fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 65.68% per jaar groeien

De winst is de afgelopen 5 jaar met 3.5% per jaar gegroeid

Risicoanalyse

Aandelen zijn zeer illiquide

Negatief eigen vermogen

Heeft minder dan 1 jaar cash runway

Heeft geen betekenisvolle marktkapitalisatie ( €98M )

+ 2 meer risico's

Clearside Biomedical, Inc. Concurrenten

Apontis Pharma

XTRA:APPH

€80.5m

Pierrel

DB:2FJ0

€92.8m

Cantourage Group

XTRA:HIGH

€56.9m

Redx Pharma

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Clearside Biomedical
Historische aandelenkoersen
Huidige aandelenkoers	US$1.09
52 Week Hoogtepunt	US$1.41
52 Week Laag	US$0.81
Bèta	2.35
11 maand verandering	0%
3 maanden verandering	7.92%
1 Jaar Verandering	n/a
33 jaar verandering	-80.88%
5 jaar verandering	n/a
Verandering sinds IPO	-89.17%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	CLM	DE Pharmaceuticals	DE Markt
7D	0%	3.7%	1.0%
1Y	n/a	-7.6%	19.0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe CLM presteerde ten opzichte van de German Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe CLM presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is CLM's price volatile compared to industry and market?
CLM volatility
CLM Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	8.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: CLM heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van CLM in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	30	George Lasezkay	clearsidebio.com

Clearside Biomedical, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Clearside Biomedical zich tot de beurswaarde?
CLM fundamentele statistieken
Marktkapitalisatie	€87.71m
Inkomsten(TTM)	-€29.97m
Inkomsten(TTM)	€6.74m

13.0x

P/S-verhouding

-2.9x

Koers/Winstverhouding

Is CLM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CLM resultatenrekening (TTM)
Inkomsten	US$7.52m
Kosten van inkomsten	US$142.00k
Brutowinst	US$7.38m
Overige uitgaven	US$40.84m
Inkomsten	-US$33.46m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.45
Brutomarge	98.11%
Nettowinstmarge	-444.66%
Schuld/Eigen Vermogen Verhouding	-165.2%

Hoe presteerde CLM op de lange termijn?

Bekijk historische prestaties en vergelijking

CLM Overzicht aandelen

Beloningen

Risicoanalyse

Clearside Biomedical, Inc. Concurrenten

XTRA:APPH

€80.5m

DB:2FJ0

€92.8m

XTRA:HIGH

€56.9m

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.15 loss in 1Q 2023)

Recent updates

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.15 loss in 1Q 2023)

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought €122k worth of stock

New minor risk - Market cap size

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Third quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 3Q 2022)

New major risk - Negative shareholders equity

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 1Q 2022)

High number of new directors

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients

Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

High number of new directors

Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients

Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 1Q 2021)

High number of new directors

Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022

Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

High number of new directors

Clearside Biomedical, Inc. Appoints Benjamin R. Yerxa to Its Board of Directors

Clearside Biomedical, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

High number of new and inexperienced directors

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2020)

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.065 loss in 1Q 2020)

Clearside Biomedical, Inc. Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

Full year 2020 earnings released: US$0.39 loss per share (vs US$0.81 loss in FY 2019)

Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (Axitinib Injectable Suspension) for the Treatment of Wet AMD